Elena Sotillo

Elena Sotillo

Auto-generated profile, based on publicly available information

Elena Sotillo

Stanford University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Nature
Verified
Journal Article
Closed access
PDF file
ATAidan M. Tousley
Aidan M. Tousley
MRMaria Caterina Rotiroti
Maria Caterina Rotiroti
LLLouai Labanieh
Louai Labanieh
LRLea Wenting Rysavy
Lea Wenting Rysavy
WKWon-Ju Kim
Won-Ju Kim
RMRobbie G. Majzner
Robbie G. Majzner

10 April 2024 in Nature
Verified
Journal Article
Open access
PDF file
ADAlexander E. Doan
Alexander E. Doan
KMKatherine P. Mueller
Katherine P. Mueller
ACAndy Y. Chen
Andy Y. Chen
GRGeoffrey T. Rouin
Geoffrey T. Rouin
YCYingshi Chen
Yingshi Chen
EWEvan W. Weber
Evan W. Weber
A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo1. The expression of memory-associated genes in CAR T cells is linked to their long-term persistence in patients and clinical efficacy2–6, suggesting that memory programs may underpin durable CAR T cell function. Here we show that the transcription factor FOXO1 is responsible for promoting memory and restraining exhaustion in human CAR T cells. Pharmacological inhibition or gene editing of endogenous FOXO1 diminished the expression of memory-associated genes, promoted an exhaustion-like phenotype and impaired the antitumour activity of CAR T cells. Overexpression of FOXO1 induced a gene-expression program consistent with T cell memory and increased chromatin accessibility at FOXO1-binding motifs. CAR T cells that overexpressed FOXO1 retained their function, memory potential and metabolic fitness in settings of chronic stimulation, and exhibited enhanced persistence and tumour control in vivo. By contrast, overexpression of TCF1 (encoded by TCF7) did not enforce canonical memory programs or enhance the potency of CAR T cells. Notably, FOXO1 activity correlated with positive clinical outcomes of patients treated with CAR T cells or tumour-infiltrating lymphocytes, underscoring the clinical relevance of FOXO1 in cancer immunotherapy. Our results show that overexpressing FOXO1 can increase the antitumour activity of human CAR T cells, and highlight memory reprogramming as a broadly applicable approach for optimizing therapeutic T cell states.

11 November 2022 in Science
Verified
Journal Article
Closed access
KFKatherine A. Freitas
Katherine A. Freitas
JBJulia A. Belk
Julia A. Belk
ESElena Sotillo
Elena Sotillo
PQPatrick J. Quinn
Patrick J. Quinn
MRMaria C. Ramello
Maria C. Ramello
CMCrystal L. Mackall
Crystal L. Mackall
T cells are the major arm of the immune system responsible for controlling and regressing cancers. To identify genes limiting T cell function, we conducted genome-wide CRISPR knockout screens in human chimeric antigen receptor (CAR) T cells. Top hits were MED12 and CCNC , components of the Mediator kinase module. Targeted MED12 deletion enhanced antitumor activity and sustained the effector phenotype in CAR- and T cell receptor–engineered T cells, and inhibition of CDK8/19 kinase activity increased expansion of nonengineered T cells. MED12 -deficient T cells manifested increased core Meditator chromatin occupancy at transcriptionally active enhancers—most notably for STAT and AP-1 transcription factors—and increased IL2RA expression and interleukin-2 sensitivity. These results implicate Mediator in T cell effector programming and identify the kinase module as a target for enhancing potency of antitumor T cell responses.

15 May 2024 in Nature
Verified
Journal Article
Open access
PDF file
SYSean A. Yamada-Hunter
Sean A. Yamada-Hunter
JTJohanna Theruvath
Johanna Theruvath
BMBrianna J. McIntosh
Brianna J. McIntosh
KFKatherine A. Freitas
Katherine A. Freitas
FLFrank Lin
Frank Lin
CMCrystal L. Mackall
Crystal L. Mackall
Adoptively transferred T cells and agents designed to block the CD47–SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system1,2. Here we administered anti-CD47 antibodies in combination with adoptively transferred T cells with the goal of enhancing antitumour efficacy but observed abrogated therapeutic benefit due to rapid macrophage-mediated clearance of T cells expressing chimeric antigen receptors (CARs) or engineered T cell receptors. Anti-CD47-antibody-mediated CAR T cell clearance was potent and rapid enough to serve as an effective safety switch. To overcome this challenge, we engineered the CD47 variant CD47(Q31P) (47E), which engages SIRPα and provides a ‘don’t eat me’ signal that is not blocked by anti-CD47 antibodies. TCR or CAR T cells expressing 47E are resistant to clearance by macrophages after treatment with anti-CD47 antibodies, and mediate substantial, sustained macrophage recruitment to the tumour microenvironment. Although many of the recruited macrophages manifested an M2-like profile3, the combined therapy synergistically enhanced antitumour efficacy. Our study identifies macrophages as major regulators of T cell persistence and illustrates the fundamental challenge of combining T-cell-directed therapeutics with those designed to activate macrophages. It delivers a therapeutic approach that is capable of simultaneously harnessing the antitumour effects of T cells and macrophages, offering enhanced potency against solid tumours.

6 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJustin A. Guerrero
Justin A. Guerrero
DKDorota D. Klysz
Dorota D. Klysz
YCYiyun Chen
Yiyun Chen
MMMeena Malipatlolla
Meena Malipatlolla
JLJameel Lone
Jameel Lone
CMCrystal L. Mackall
Crystal L. Mackall
The intensive nutrient requirements needed to sustain T cell activation and proliferation, combined with competition for nutrients within the tumor microenvironment, raise the prospect that glucose availability may limit CAR-T cell function. Here, we seek to test the hypothesis that stable overexpression (OE) of the glucose transporter GLUT1 in primary human CAR-T cells would improve their function and antitumor potency. We observe that GLUT1OE in CAR-T cells increases glucose consumption, glycolysis, glycolytic reserve, and oxidative phosphorylation, and these effects are associated with decreased T cell exhaustion and increased Th17 differentiation. GLUT1OE also induces broad metabolic reprogramming associated with increased glutathione-mediated resistance to reactive oxygen species, and increased inosine accumulation. When challenged with tumors, GLUT1OE CAR-T cells secrete more proinflammatory cytokines and show enhanced cytotoxicity in vitro, and demonstrate superior tumor control and persistence in mouse models. Our collective findings support a paradigm wherein glucose availability is rate limiting for effector CAR-T cell function and demonstrate that enhancing glucose availability via GLUT1OE could augment antitumor immune function.

17 June 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CMCrystal L. Mackall
Crystal L. Mackall
CBCatherine M. Bollard
Catherine M. Bollard
NGNancy Goodman
Nancy Goodman
CCCasey Carr
Casey Carr
RGRebecca Gardner
Rebecca Gardner
DKDonald Kohn
Donald Kohn